Procedure Deep-Dive · November 20, 2026

Amyloidosis and Cosmetic Surgery: Periorbital Purpura, Macroglossia, Lichen Amyloidosis, Carpal Tunnel, Lasers, Fillers, Anesthesia, and Bleeding

Amyloidosis rarely announces itself to a cardiologist first. It shows up as bruising around the eyes, a tongue with tooth marks along its edges, numb hands that needed carpal tunnel surgery on both sides, or itchy brown bumps on the shins. Many of those complaints land in a cosmetic consultation room before they land anywhere else. Here is what the disease is, which signs should stop an elective plan, and how patients with a confirmed diagnosis can approach lasers, fillers, and surgery safely.

By The Editorial Desk

18 min read

A man in his late fifties with short silver-gray hair and a trimmed gray beard, wearing a dark green crew-neck sweater, seated in a wooden chair beside a bright window with his arms folded on a small round wooden table that holds a folded newspaper, looking thoughtfully toward the camera in soft natural light

He is 61 and books a consultation for his eyes. The skin around them bruises for no reason he can name, sometimes after a coughing fit, sometimes after he rubs them in the morning, and the purple rings make him look, in his words, "like I lost a fight." He wants the dark circles treated and maybe the lower lids tightened. Later in the visit he mentions that he had carpal tunnel surgery on both hands in the last four years, that his ankles swell by evening, that he gets winded on the stairs to his office, and that he has lost about fifteen pounds without trying. He is pleased about the weight.

None of that sounds like a cosmetic problem, and that is precisely the point. Spontaneous bruising around the eyes, bilateral carpal tunnel syndrome, swelling, breathlessness, and unexplained weight loss in the same man are a classic cluster for systemic amyloidosis, a disease in which misfolded proteins pile up in the heart, kidneys, nerves, and skin. A lower blepharoplasty would not touch the cause. Under general anesthesia, an undiagnosed amyloid heart can respond to an ordinary drop in blood pressure in ways that are very hard to reverse.

A second patient carries a gentler version of the same word. She is 38, with a rippled, brownish patch across her upper back and itchy, rough bumps on both shins that she has been told were eczema, then "just pigment." A biopsy finally named it: macular amyloidosis on the back and lichen amyloidosis on the legs, forms that stay in the skin and do not involve the organs at all. She wants lasers. For her, the question is not cardiac risk. It is which treatments actually help and which will leave her darker than she started.

Same word, very different stakes. Sorting out which kind of amyloidosis is in the room is the whole job.

What amyloidosis is, and why the type changes everything

The short answer: amyloidosis is a group of diseases in which a specific protein misfolds into stiff fibrils that deposit in tissue, and the type of protein decides whether the problem is a cosmetic nuisance confined to the skin or a life-threatening illness of the heart, kidneys, and nerves.

The word describes a final common pathway, not a single disease. Under the microscope, every type of amyloid shares one property: when tissue is stained with Congo red dye and viewed under polarized light, the deposits glow an apple-green color. That stain is how the diagnosis is made. What differs is the protein that misfolded, and that protein determines the organs involved, the treatment, and the prognosis.

The forms a cosmetic patient or surgeon is most likely to meet:

  • AL amyloidosis (light chain): a small population of abnormal plasma cells in the bone marrow produces fragments of antibody called light chains, which misfold and deposit in the heart, kidneys, liver, nerves, gut, and soft tissue. It is related to multiple myeloma, and some patients have both. AL is the type behind most of the visible signs on the face: purpura around the eyes, an enlarged tongue, and waxy bumps on the eyelids. It is rare, with incidence usually estimated at around 10 to 12 new cases per million people per year, but it is serious, and untreated cardiac AL can be fatal within months.
  • ATTR amyloidosis (transthyretin): transthyretin is a transport protein made by the liver. In wild-type ATTR, the normal protein becomes unstable with age and deposits mainly in the heart and in ligaments, overwhelmingly in men over 60. Autopsy studies have found transthyretin deposits in the hearts of a substantial share of people over 80, and cardiologists now believe the condition was badly underdiagnosed for decades. In hereditary ATTR, a gene variant makes the protein unstable earlier. One variant, often written V122I (also called Val142Ile), is carried by roughly 3 to 4 percent of Black Americans and raises the risk of heart failure later in life.
  • AA amyloidosis: the deposits come from serum amyloid A, a protein the liver makes during inflammation. It follows years of uncontrolled chronic inflammation, from rheumatoid arthritis and inflammatory bowel disease to chronic skin infection. Severe, long-standing hidradenitis suppurativa and the repeated skin abscesses that come with injecting drugs under the skin are both recognized causes. It mainly attacks the kidneys.
  • Dialysis-related amyloidosis: in people on dialysis for many years, a protein called beta-2 microglobulin accumulates in joints and tendons, classically producing carpal tunnel syndrome and bone cysts. Anyone with chronic kidney disease or a dialysis history already brings a long list of considerations to elective surgery, and this is one more.
  • Primary localized cutaneous amyloidosis: the deposits stay in the skin and never involve internal organs. Lichen amyloidosis produces intensely itchy, firm, brownish bumps, usually on the shins. Macular amyloidosis produces a gray-brown, rippled or net-like discoloration, usually on the upper back, and is strongly associated with chronic friction, including nylon scrub brushes and rough towels. Both are more common in people of Asian, Hispanic, and Middle Eastern descent and in darker skin types. Nodular amyloidosis is different: a waxy, sometimes yellow or pink nodule caused by a localized cluster of plasma cells making light chains. It usually stays local, but a minority of patients in published series later develop systemic disease, so it deserves blood testing and follow-up.

The practical upshot is that "I have amyloidosis" is not enough information for anyone planning a procedure. The patient with macular amyloidosis on her back has no more anesthetic risk than her neighbor. The patient with cardiac AL or ATTR may be one of the highest-risk people a cosmetic surgeon will ever see.

"Amyloidosis is a protein problem wearing many costumes. In the skin forms it is a cosmetic and itching problem. In the systemic forms, the face is often just the place where a heart and kidney disease first becomes visible."

The signs that should stop a cosmetic plan

The short answer: spontaneous bruising around the eyes, an enlarged or tooth-marked tongue, waxy eyelid bumps, carpal tunnel syndrome in both hands, unexplained swelling or breathlessness, and weight loss together are red flags for systemic amyloidosis, and they call for a medical workup before any elective procedure, not a filler or a lid lift.

Systemic amyloidosis is notorious for a slow diagnosis. Surveys of patients with AL amyloidosis have repeatedly found that many saw several doctors over a year or more before anyone named the disease, and the delay matters because outcomes depend heavily on how much of the heart is already involved at diagnosis. Cosmetic providers see faces, eyelids, hands, and skin in close detail. They are, occasionally, the first trained eyes on the evidence.

Periorbital purpura. Amyloid deposits in the walls of small blood vessels make them fragile, and in AL amyloidosis this can produce purple bruising around the eyes after minor strain: coughing, vomiting, straining, bending over, or even rubbing the eyelids. It is often called "raccoon eyes," and it appears in a minority of AL patients, commonly cited at around 15 percent. A related sign is "pinch purpura," in which gently pinching the skin leaves a bruise. Purpura around both eyes in an adult without trauma is not a dark-circle problem, and it should never be the opening case for under-eye filler or a treatment plan for dark circles.

Macroglossia. An enlarged tongue occurs in roughly 10 to 20 percent of people with AL amyloidosis. Early on it may be subtle: scalloping along the edges where the tongue presses into the teeth, a feeling that the tongue is too big for the mouth, new snoring, difficulty chewing, or slurred speech. Some patients first notice it as a change in the lower face or a fuller area under the chin. It does not occur in ATTR, which is one reason it is such a useful clue.

Skin and soft tissue clues. AL amyloidosis can cause smooth, waxy, translucent papules on the eyelids, around the nose and mouth, and in skin folds, sometimes with bleeding into them. It can also enlarge the submandibular glands, harden the soft tissue at the front of the shoulders (the "shoulder pad sign"), thicken or distort nails, and thin the hair. Eyelid and conjunctival amyloid deposits can also mimic a droopy lid or a stubborn lump, which is one reason a firm, yellowish or salmon-colored eyelid mass that behaves unlike a chalazion, or a ptosis with an unusual feel, should be biopsied rather than simply removed and discarded. It is also why the pathology report after a cosmetic procedure is worth reading.

The hand surgery history. Carpal tunnel syndrome is common, but carpal tunnel syndrome in both hands, especially in a man over 50, is now recognized as an early warning sign of wild-type ATTR amyloidosis, often appearing five to ten years before heart failure. In a 2018 study in the Journal of the American College of Cardiology, surgeons sent tissue from carpal tunnel release operations for amyloid staining in men over 50 and women over 60; about 10 percent were positive, and some of those patients already had cardiac involvement. Trigger fingers, spinal stenosis, and a spontaneous rupture of the biceps tendon belong to the same pattern. The American College of Cardiology's 2023 expert consensus on cardiac amyloidosis lists these orthopedic histories as red flags worth asking about. A patient seeking hand rejuvenation with two carpal tunnel scars and numb fingertips deserves at least one question about the heart.

The system review. The rest of the cluster is easy to miss because each item is common: ankle swelling, shortness of breath on exertion, lightheadedness on standing, foamy urine (protein loss from the kidneys), numbness or burning in the feet, diarrhea alternating with constipation, early fullness when eating, an enlarged liver, and unexplained weight loss. A face that has hollowed out quickly can be blamed on age or on GLP-1 drugs, and the patient may arrive asking about volume loss and facial hollowing. If the patient is not on one of those drugs and is not dieting, rapid facial wasting is a symptom, not a cosmetic concern.

When several of these signs line up, the appropriate next step is a primary care visit, ideally with a direct letter from the cosmetic provider describing what was seen. The screening tests are blood and urine studies that look for an abnormal monoclonal protein (serum and urine protein electrophoresis with immunofixation, plus a serum assay of kappa and lambda light chains), along with an electrocardiogram, echocardiogram, and blood markers of heart strain such as NT-proBNP and troponin. If no monoclonal protein is found and the heart looks suspicious, a nuclear bone scan with a tracer such as technetium pyrophosphate can diagnose cardiac ATTR without a heart biopsy. If a monoclonal protein is present, tissue confirmation is required, often from a quick needle aspiration of abdominal fat.

That last detail has an odd relevance for body contouring. Abdominal fat is a standard place to look for amyloid because it is easy to reach and often contains deposits in systemic disease. A patient who is already under investigation and also planning a tummy tuck or liposuction, and who is working through the usual preoperative testing, should not be using the operation as a diagnostic shortcut, but if the hematologist agrees, it is reasonable to ask whether the removed tissue can go to pathology with a specific request for Congo red staining. The sequence still has to run in the right order: diagnosis and treatment first, elective surgery much later, if at all.

Lasers, peels, and itch control in lichen and macular amyloidosis

The short answer: the skin-limited forms of amyloidosis are safe to treat cosmetically, but they respond slowly, they relapse when friction and scratching continue, and in darker skin the main risk of aggressive lasers and peels is pigment that ends up worse than the original problem.

For the patient whose amyloidosis lives only in the skin, the conversation changes entirely. These are chronic, frustrating conditions that are hard on quality of life. Lichen amyloidosis itches enough to disrupt sleep, and the scratching itself drives more deposits, creating a loop dermatologists call the itch-scratch cycle. Macular amyloidosis rarely itches much but is visible, persistent, and frequently mistaken for post-inflammatory pigment, melasma, or a fungal infection.

Before any device touches the skin, the diagnosis should be confirmed by biopsy. Lichen amyloidosis can look like lichen simplex chronicus, hypertrophic lichen planus, or prurigo nodularis. Macular amyloidosis can look like melasma, post-inflammatory hyperpigmentation, or a drug-related darkening. A wrong label leads to the wrong laser.

The general treatment logic, drawn from the dermatology literature, which consists mostly of small case series rather than large trials:

  • Stop the friction first. For macular amyloidosis, that means throwing out the loofah, the nylon back brush, and the rough exfoliating cloth. For lichen amyloidosis, it means controlling itch aggressively enough that the patient stops scratching. Treating the pigment while the friction continues is like mopping during a leak.
  • Medical itch control. Potent topical steroids, often under occlusion with a plastic wrap or hydrocolloid dressing, steroid injections into thick lesions, topical calcineurin inhibitors, capsaicin, and phototherapy have all been used. Newer anti-itch agents used for related conditions are being studied, but the evidence specific to amyloidosis is limited.
  • Ablative resurfacing for thick lichen amyloidosis. Fractional CO2 and erbium lasers and old-fashioned dermabrasion have been reported to flatten raised lesions and reduce itch, presumably by physically removing the amyloid-laden upper dermis. The tradeoff is the familiar one from any ablative versus non-ablative resurfacing decision: deeper treatment means longer healing and a higher risk of scarring and pigment change.
  • Pigment-targeting lasers for macular amyloidosis. Q-switched and picosecond Nd:YAG lasers, among others, have been reported to lighten macular amyloidosis in small studies. Results are variable, multiple sessions are usually needed, and recurrence is common if friction resumes. The principles overlap with any plan for lasers for sun spots and pigmentation, except that the target is not purely melanin.

The skin types most affected by localized cutaneous amyloidosis are also the skin types most prone to post-inflammatory hyperpigmentation after heat, inflammation, and injury. That makes test spots, conservative energy settings, strict sun protection, and a willingness to stop after a few sessions essential. A provider who promises clearance in one aggressive treatment is promising something the published evidence does not support.

There is also one cosmetic-adjacent cause of localized amyloid worth knowing about: injection-site amyloidosis. Repeated injections of insulin into the same spot can produce a firm lump of amyloid made from insulin itself, and the lump absorbs the drug poorly. Similar localized deposits have been described with a few other repeatedly injected drugs. A patient who asks to have a "fatty lump" on the abdomen liposuctioned or excised, and who injects insulin there, may have an insulin-derived amyloid mass, and rotating injection sites matters as much as removing it.

Fillers, toxin, eyelid surgery, and bruising in systemic disease

The short answer: in systemic amyloidosis, especially AL, fragile blood vessels and sometimes an acquired clotting factor deficiency make bruising and bleeding the main problem with injectables and eyelid work, and the treating hematologist or cardiologist should approve even minor procedures.

Patients with treated, stable systemic amyloidosis are not banned from cosmetic care forever. Some respond well to treatment, live for many years, and want to look less ill. But the disease changes the risk of almost every procedure in specific, predictable ways.

Fragile vessels. The same vessel fragility that causes periorbital purpura means that needles, cannulas, and even firm pressure can produce disproportionate bruising. Under-eye filler, temple filler, and lip filler in a patient with active purpura can create bruises that last weeks and that can be hard to distinguish from a vascular event. The baseline risks of filler vascular occlusion do not disappear, and the recognition of those events relies partly on reading skin color, which purpura muddies. Blunt cannulas, smaller volumes, ice, and a long time between sessions are sensible, and many experienced injectors simply defer treatment while purpura is active.

Acquired factor X deficiency. In a subset of AL patients, factor X, one of the clotting proteins, binds to amyloid deposits and disappears from the circulation. The result is a true bleeding disorder that looks, on routine tests, like a prolonged PT and PTT. Estimates of how often it occurs vary widely across case series, but it is well documented and can be severe. Anyone with AL amyloidosis should have recent coagulation studies before a procedure that could bleed, and a surgeon should treat an unexplained abnormal clotting test the way the bleeding disorders literature recommends: as a reason to stop and investigate, not as a lab error.

Anticoagulants. Atrial fibrillation is very common in cardiac amyloidosis, and blood clots form in the heart's upper chambers so readily that many patients are on anticoagulants regardless of the usual risk scores. Stopping those drugs for an elective cosmetic procedure is a cardiology decision, not a cosmetic one, and the general approach to blood thinners before cosmetic surgery applies with extra caution because the stroke risk of interruption is higher than average.

Eyelid surgery. A lower blepharoplasty in a patient with periorbital purpura and possible factor X deficiency combines fragile tissue, bleeding risk, and an area where a hematoma behind the eye can threaten vision. Any blepharoplasty for sagging skin or under-eye bags in someone with known AL amyloidosis should be planned with the hematologist, with clotting tests checked shortly before surgery, and many surgeons would reasonably decline. A droopy upper lid needs particular care, because ptosis from amyloid deposits in the eyelid muscles is a reported cause and is not fixed by removing skin; the distinction in eyelid ptosis versus blepharoplasty matters more here than usual.

Botulinum toxin. Toxin itself has no known interaction with amyloid, but systemic amyloidosis can cause peripheral and autonomic neuropathy and muscle weakness. Patients with significant neuropathy or weakness should be assessed before treatment, and the injection technique should account for bruising risk. For skin-limited amyloidosis, toxin is not a concern.

Tongue reduction and the lower face. Macroglossia can be severe enough to obstruct the airway, block chewing, or interfere with speech, and in carefully selected patients with controlled disease, surgical tongue reduction has been reported. That is a functional head and neck operation performed with the hematologist, not a cosmetic procedure, and it does not belong in a med spa or an office-based setting.

Anesthesia, cardiac amyloid, and the problem with low blood pressure

The short answer: cardiac amyloidosis makes the heart stiff and unable to compensate for drops in blood pressure, fluid shifts, or rhythm changes, so general anesthesia and large-volume body contouring carry real risk, and elective cosmetic surgery should generally wait until the disease is treated, stable, and cleared by a cardiologist who understands amyloid.

The heart in cardiac amyloidosis becomes thick and rigid as deposits infiltrate the muscle. It fills poorly, and its output depends heavily on adequate filling pressure and a steady heart rate. Many patients also have autonomic neuropathy, which removes the reflexes that normally tighten blood vessels when blood pressure falls, and they may be dehydrated from diuretics or losing protein through the kidneys. The result is a patient who can tolerate ordinary life reasonably well and then collapse in response to an ordinary anesthetic induction.

The anesthesia literature on amyloidosis, including reports from centers that perform biopsies and transplants in these patients, emphasizes several points:

  • Low blood pressure is poorly tolerated. Induction agents that relax blood vessels, deep sedation, and spinal or epidural anesthesia can all drop blood pressure sharply, and an amyloid heart cannot always recover. Careful drug choice, slow titration, invasive blood pressure monitoring in significant disease, and drugs ready to support circulation are standard.
  • Rhythm problems are common. Atrial fibrillation, heart block, and dangerous ventricular rhythms occur, and some patients have pacemakers or defibrillators that need management around electrocautery.
  • Fluid is a two-sided problem. Too little and the stiff heart cannot fill. Too much and the patient goes into heart failure. That tension is the central reason large-volume liposuction, with its tumescent fluid load and its later fluid shifts, is a poor fit for cardiac amyloidosis. The considerations overlap with those in our piece on heart failure and cosmetic surgery, with the added problem that amyloid hearts often have a normal ejection fraction, which can make the echocardiogram look falsely reassuring to someone who is not looking for the telltale thickening.
  • Local anesthetic load deserves attention. Large doses of lidocaine in tumescent fluid depend on normal liver blood flow and heart function for safe clearance, and the warning signs of lidocaine toxicity in tumescent liposuction include rhythm disturbances that a diseased heart handles badly.
  • The airway may be difficult. Macroglossia, enlarged submandibular glands, and amyloid in the larynx can make intubation and mask ventilation hard, and the same anatomy raises the risk of obstruction after sedation. Patients with an enlarged tongue should be evaluated much as patients with sleep apnea are, with an airway plan made in advance.
  • Kidney involvement changes drug dosing and healing. AL and AA amyloidosis frequently cause nephrotic syndrome, with heavy protein loss, low blood albumin, and swelling. Low albumin slows wound healing and makes tissue edema worse, which is the opposite of what any body contouring patient wants.

Treatment timing. The treatment landscape has improved dramatically. For AL amyloidosis, chemotherapy-based regimens aimed at the plasma cell clone, now commonly including the antibody daratumumab, and in selected patients stem cell transplantation, can bring the light chains down and allow organs to recover. For ATTR cardiomyopathy, stabilizer drugs such as tafamidis and acoramidis, and gene-silencing drugs such as vutrisiran, slow progression. These treatments matter for cosmetic planning in two ways. Their side effects, including low blood counts, infection risk, neuropathy, and fatigue, affect healing and anesthesia, much as they do in patients considering cosmetic surgery after chemotherapy. And successful treatment can turn a prohibitive risk into an acceptable one over time, so "not now" is often more accurate than "never."

Where and how. For a patient with cardiac involvement who still has a strong reason for a procedure, the honest options shrink to smaller operations under local anesthesia with minimal sedation, or hospital-based surgery with cardiac anesthesia support. Office-based general anesthesia for a combined body contouring case is not a reasonable choice. The questions in our guides to anesthesia choice and the operative plan, outpatient facility accreditation, and hospital privileges become far more than formalities. And because age is the biggest risk factor for wild-type ATTR, the general cautions in our piece on age and cosmetic surgery apply: a fit 70-year-old may do very well, but a 70-year-old with bilateral carpal tunnel scars, swollen ankles, and an unexplained thick heart wall on an old echo needs answers before an operating room date.

The honest summary

Amyloidosis is uncommon, but it is not as rare as it once seemed, especially the age-related transthyretin form in older men and the hereditary variant carried by a meaningful share of Black Americans. The first job in any cosmetic setting is to identify which type is involved, because the skin-limited forms and the systemic forms share a name and almost nothing else.

Lichen and macular amyloidosis are chronic skin conditions that can be treated cosmetically with patience: biopsy first, stop the friction, control the itch, and approach lasers and resurfacing conservatively, with pigment risk in darker skin as the main hazard. Nodular amyloidosis and injection-site amyloid lumps deserve a little more investigation, but they do not usually change the safety of anesthesia.

Systemic amyloidosis is different. Its earliest signs often look cosmetic: purple bruising around the eyes, a tongue that has grown, waxy bumps on the eyelids, a face that hollowed out without dieting, two carpal tunnel scars on a man in his sixties. Any provider who sees that cluster and offers filler or a lid lift has missed the diagnosis that matters. For patients with confirmed AL or ATTR disease, fragile vessels, factor X deficiency, anticoagulation, a stiff heart that cannot handle low blood pressure, and kidney protein loss make elective surgery a decision for the hematologist and cardiologist first and the surgeon second.

None of this means a patient with amyloidosis can never have a cosmetic procedure. Treated, stable patients do have them. But the order is fixed: diagnosis, treatment, stability, specialist clearance, a facility that can manage a fragile heart, and only then the procedure. If a provider is willing to skip any of those steps, get a second consultation before anyone picks up a needle.